Gamma-aminobutyric acid type A receptor alpha-2 and alpha-3 subunits (GABA(A)R α2/α3)

Gamma-aminobutyric acid type A (GABAA) receptors are pentameric ligand-gated chloride channels that serve as the primary mediators of fast inhibitory neurotransmission in the central nervous system [1.4.1]. These receptors are composed of various subunits, with those containing the alpha-2 (α2) and alpha-3 (α3) subunits being of particular therapeutic interest due to their distinct physiological roles and anatomical distribution [1.2.1]. While α1-containing receptors are widely distributed and associated with the sedative, hypnotic, and amnestic effects of benzodiazepines, α2 and α3 subunits are predominantly localized in the limbic system and spinal cord, where they modulate anxiety, muscle tone, and pain signaling [1.2.2, 1.3.2]. Targeting these specific subunits with positive allosteric modulators (PAMs) aims to achieve "anxioselective" and analgesic effects while avoiding the sedation and abuse liability typically associated with non-selective GABAA receptor ligands [1.3.1, 1.3.4]. Research into α2/α3-selective compounds has highlighted their potential in treating generalized anxiety disorder, chronic pain, and epilepsy [1.2.3, 1.3.2]. Furthermore, these receptors are implicated in the pathophysiology of schizophrenia and essential tremor, making them versatile targets for neuropsychiatric drug development [1.3.3, 1.3.4].

Other names

GABRA2GABRA3GABA(A) receptor alpha-2/3Alpha-2/3-containing GABAA receptorsα2/α3-GABAAR

Positive allosteric modulation (PAM) at the benzodiazepine binding site located at the interface of the alpha and gamma subunits [1.2.1, 1.3.5].